Pharma Could Cut Its Losses with a Bit of Sharing
Efforts to engage life science companies in open innovation have been hampered by the industry’s continued reticence to share. The result is shrinking pipelines, a wave of drug patent expirations ending in sudden drops in revenue, and poorly served public health.